Lupin Manufacturing Solutions Limited (LMS), a 100% subsidiary of Lupin Limited, is a leading manufacturer of active pharmaceutical ingredients (APIs) and a global contract development and manufacturing organization (CDMO) offering standalone & integrated solutions across drug substance, complex chemistry, drug product and advanced modalities including ADCs and peptides. Leveraging Lupin’s legacy of scientific rigor and regulatory expertise, LMS supports biopharma innovators from early
development to commercial scale. With state-of-the-art facilities, a client-first approach and a team of 250+ scientists, LMS accelerates the path to market for transformative therapies.

Company (Headquarters):

India

Types of Drugs Manufactured:

Small Molecule

CDMO Services:

Drug Substance Manufacturing (API);Drug Product/FDF;Research & Development;Packaging(Commercial);Regulatory Services;Analytical Development;Packaging (Clinical);Process & Forumulation Development

Therapeutic Area:

Cardiovascular;Central Nervous System;Dermatology;Ear Nose Throat and Oral health;Endocrine and Hormonal;Gastrointestinal and Metabolism;Genito Urinary and Women’s Health;Hematology;Immunology;Infectious Disease;Musculoskeletal System;Nutritional;Oncology;Ophthalmology;Rare and Genetic Disorders;Respiratory

CDMO Number of Facilities:

3

High Potent Products capabilities:

OEB 3 Medium Potency;OEB 4-5 Highly Potent APIs (HPAPIs)

Facilities Location:

South Asia

Manufacturing Technologies:

Cartridges;Creams/Gels/Ointments;Inhalers;Lyophilized amps/vials;Oral Liquids;Pre-Filled Syringes (PFS);Sterile Ampoules;Sterile Vials;Tablets/Capsules